Fludara Articles
US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL
19 February 2010
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
22 January 2010
MabThera for leukemia OKed in Scotland
8 June 2009
Antisoma's six-month revenue drops 67%
2 March 2009
BLA submitted for GSK and Genmab's Arzerra
9 February 2009
Antisoma's CLL tablet approved by US FDA
12 January 2009
Ofatumumab sees positive Ph III CLL data
11 August 2008
Zevalin follow-up results in 96% remission in NHL
24 March 2008
Xanthus' oral fludarabine NDA accepted by FDA
4 February 2008
Protherics and Advancell enroll Acadra Ph I/II trial
21 January 2008
Ph I/II trial of Acadra enrolls first B-CLL patient
21 January 2008
Bayer's MabCampath cleared for CLL by EC
14 January 2008
132 patients enter pivotal study of Genmab CLL drug
10 December 2007
CHMP advocates MabCampath approval
29 October 2007
Abraxis gains two FDA OKs for fludarabine
22 October 2007
Alemtuzumab cuts relapse risk in RRMS
22 October 2007
FDA approves Campath as single agent for B-CLL
1 October 2007
FDA fast-tracks Cell Thera's pixantrone
21 May 2007
Santaris' SPC2996 active in animal model of CLL
23 April 2007
Genzyme/Bayer file for Campath label expansion
16 April 2007
Bayer's oral Fludara gets MHLW approval
5 February 2007
Takeover costs impact Schering AG's 1st-half 2006
31 July 2006
Takeover costs impact Schering's 1st-half 2006
26 July 2006
Genmab's HuMax-CD20 enters pivotal Ph III trial
5 June 2006
Genasense shows benefits in CLL trial
27 February 2006
BioCryst's Fodosine starts Ph II trial in CLL
5 September 2005
Genta starts NDA for Genasense Injection
11 July 2005
Sanofi-Aventis/Genta stop Genasense deal
15 November 2004
Update: Sales up 11% at Schering AG
10 March 2003
Fludara cleared for first-line use in CLL
17 February 2003
New data on Ligand's Targretin, Ontak
27 May 2002
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Schering's Campath shows potential for treatment of T-PLL
3 October 2001
New NICE guidance on Fludara in CLL; breast cancer advice on taxanes to
25 September 2001
Schering AG raises earnings expectations
27 July 2001
Millennium net loss reaches $30.7 million
19 July 2001
M&I's MabCampath is approved by EMEA
12 July 2001
Schering AG 1st-qtr net income rises 19%
25 April 2001
MabCampath nears EU approval for CLL
30 March 2001
Schering AG to "grow faster than market"
16 March 2001
Campath approval delayed in USA
21 February 2001
Oral Fludara launched in first market
22 January 2001
BTG's Campath nears approval in USA
15 December 2000
1999 sales and profits up at Schering AG - updated story
10 February 2000
Schering AG acquires Mitsui Pharma
12 January 2000
NCI begins trial of Genta's G3139 in leukemia
13 December 1999
Schering AG sales up 9% for 1st nine months
11 November 1999
LeukoSite Lead Product May Be On Market By 2000
28 May 1998
Strong Start To 1998 By Schering AG
5 May 1998
Schering AG Sales And Profits Rise In 1997
20 March 1998
Israel OKs Extra Funding For New Drug Therapies
12 January 1998
Gyne/Therapeutics Push Schering AG First Half Sales
7 August 1997
Oncology And LeukoSite Form JV For CLL
19 May 1997
Schering AG Posts 13% Sales Hike For 1996
17 February 1997
Difficult Times As Schering AG Marks 125 Years
1 July 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
No Drug Approval Lag, "At Least Not In The USA"
18 December 1995
Beleaguered Dutch Pharma Market Manages 5% Growth
21 August 1995
Flat Interim Results From Schering AG
14 August 1995
Schering Launches Fludara In UK
31 October 1994
SCHERING AG SEES PROFITS DIP
14 February 1994
GOOD 1993 FIRST HALF FOR SCHERING AG
16 August 1993
AGROCHEMICALS PULL SCHERING DOWN
22 February 1993
1991 "BETTER THAN EXPECTED" AT SCHERING
22 June 1992
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
Showing 1-85 of 85 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
